Clinical Trials Logo

Clinical Trial Summary

Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment

Treatment Group:

Subjects treated with aBMC using the CardiAMP cell therapy system

Sham Control Group:

Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03455725
Study type Interventional
Source BioCardia, Inc.
Contact Peter Altman, PhD
Phone (650) 226 0135
Status Not yet recruiting
Phase Phase 3
Start date December 2018
Completion date December 2026

See also
  Status Clinical Trial Phase
Completed NCT01205893 - Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA Phase 2
Completed NCT00694642 - Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis Phase 1/Phase 2
Suspended NCT00820586 - Intramyocardial Delivery of Autologous Bone Marrow Phase 2
Completed NCT01966042 - Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina Phase 2
Recruiting NCT03218891 - Cardiac Rehabilitation in Patients With Refractory Angina N/A
Completed NCT01796912 - Lipoprotein Apheresis in Refractory Angina Study N/A
Recruiting NCT03350737 - Coronary Arteriogenetic Heparinized Exercise N/A
Recruiting NCT01566175 - Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization N/A